International Clinical Trial: GATE-251 or Placebo for the Reduction of Symptoms of Major Depressive Disorder With Comorbid Anxiety and Insomnia

Geneva, Aug. 29 -- International Clinical Trials Registry received information related to the study (NCT07115329) titled 'GATE-251 or Placebo for the Reduction of Symptoms of Major Depressive Disorder With Comorbid Anxiety and Insomnia' on Aug. 4.

Study Type: Interventional

Study Design: Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).

Primary Sponsor: Syndeio Biosciences, Inc

Condition: Major Depressive Disorder

Intervention: Drug: Zelquistinel

Recruitment Status: Not recruiting

Phase: Phase 2

Date of First Enrollment: September 2025

Target Sample Size: 164

Countries of Recruitment: United States...